Curis, Inc. (CRIS) Receives $24.33 Consensus Target Price from Analysts

Shares of Curis, Inc. (NASDAQ:CRIS) have been assigned an average rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $24.33.

Several brokerages have issued reports on CRIS. Zacks Investment Research upgraded shares of Curis from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Tuesday, July 31st. Cowen restated a “buy” rating on shares of Curis in a research report on Tuesday, September 25th. ValuEngine downgraded shares of Curis from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Finally, SunTrust Banks dropped their price target on shares of Curis to $8.00 and set a “buy” rating for the company in a research report on Friday, August 3rd.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co acquired a new stake in shares of Curis in the second quarter valued at approximately $223,000. LMR Partners LLP acquired a new stake in shares of Curis in the second quarter valued at approximately $124,000. Finally, Millennium Management LLC acquired a new stake in shares of Curis in the second quarter valued at approximately $540,000. Institutional investors own 33.49% of the company’s stock.

Shares of CRIS stock opened at $2.06 on Wednesday. The company has a debt-to-equity ratio of 4.43, a current ratio of 3.01 and a quick ratio of 3.01. The company has a market cap of $69.35 million, a price-to-earnings ratio of -1.14 and a beta of 1.11. Curis has a 12-month low of $1.36 and a 12-month high of $8.70.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.15. The firm had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.41 million. Curis had a negative net margin of 407.29% and a negative return on equity of 225.77%. On average, sell-side analysts anticipate that Curis will post -1.18 EPS for the current fiscal year.

Curis Company Profile

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Featured Story: What are the risks of holding treasury bonds?

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply